Setmelanotide vs Bivamelagon
Written by Aaron CuhaReviewed Sep 2026
The short answer
An FDA approved shot that turns on the MC4R switch, against a pill that does the same. The pill had a 28 person early trial that finished in February 2026, with no results posted and no peer reviewed paper on it at all. Taking it by mouth is the selling point. The gap in evidence is the fact.
- Setmelanotide people
- 38
- Setmelanotide nulls
- 0
- Bivamelagon people
- 0
- Bivamelagon nulls
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved (Imcivree) for certain rare genetic causes of obesity
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
SetmelanotideSetmelanotide (MC4R agonist)
An FDA-approved shot for rare genetic types of obesity, where a broken gene stops the brain from feeling full.
Column B
BivamelagonBivamelagon (LB54640), oral melanocortin-4 receptor agonist
A pill meant to turn down appetite. It works on the same brain switch, called MC4R, as setmelanotide, which is a shot. A 28 person study in people whose obesity came from brain damage finished in February 2026. No results have been posted. Nothing on this drug has been published in a science journal.
Side by side, on the facts we can check
| What we compare | Setmelanotide | Bivamelagon |
|---|---|---|
| Category | Melanocortin | Melanocortin |
| FDA status | FDA-approved (Imcivree) for certain rare genetic causes of obesity | Not FDA approved. Investigational. A mid-stage study in hypothalamic obesity, which comes from damage to the part of the brain that controls hunger, is finished with no results posted. A follow-on study, where everyone knows they are getting the drug, is signing people up (September 2026). |
| Half-life | ~11 hours | Not reported |
| Molecular weight | 1,117.3 Da | Not reported |
| How it works | It switches on MC4R, the brain's fullness switch. That brings back the fullness signal that the broken genes shut off. | In people, drugs in this family turn down appetite by switching on MC4R in the brain. Some rare gene faults, in POMC, PCSK1 and LEPR, break the chain of signals that leads to this switch. Setmelanotide works by flipping the switch anyway. The company says bivamelagon hits MC4R and not much else, and that it works as a pill. No lab data, blood level data or dose data on bivamelagon has been published. So this explanation comes from the drug family and the company, not from data on this drug. In monkeys, a 2026 study of a different pill found that hitting MC3R as well as MC4R caused more weight loss than MC4R alone. That tells you about the appetite system in monkeys. It says nothing direct about bivamelagon. |
| Studies in people | 2 | 4 |
| Evidence | Limited: 1 completed trial, 38 people given it | Limited: 1 completed trial, none stating how many people |
| Legal status, US | FDA-approved, prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Setmelanotide and Bivamelagon?
Setmelanotide: An FDA-approved shot for rare genetic types of obesity, where a broken gene stops the brain from feeling full. Bivamelagon: A pill meant to turn down appetite. It works on the same brain switch, called MC4R, as setmelanotide, which is a shot. A 28 person study in people whose obesity came from brain damage finished in February 2026. No results have been posted. Nothing on this drug has been published in a science journal.
Which has stronger research evidence, Setmelanotide or Bivamelagon?
Each compound gets a band worked out from facts we counted, with the math shown. Setmelanotide is Limited (1 completed trial, 38 people given it). Bivamelagon is Limited (1 completed trial, none stating how many people). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Setmelanotide and Bivamelagon FDA-approved?
Setmelanotide: FDA-approved (Imcivree) for certain rare genetic causes of obesity. Bivamelagon: Not FDA approved. Investigational. A mid-stage study in hypothalamic obesity, which comes from damage to the part of the brain that controls hunger, is finished with no results posted. A follow-on study, where everyone knows they are getting the drug, is signing people up (September 2026)..
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.